CHINA CINDA (01359): Wang Pengcheng approved to serve as independent non-executive director
China Xinda (01359) has announced that the company has recently received approval from the financial regulatory bureau for Mr. Wang Pengcheng (Mr. Wang) to serve as the company's independent non-executive director (Approval No. [2026]360). As a result, Mr. Wang will serve as the company's independent non-executive director. His appointment as a director will take effect from July 4, 2026, for a term of three years, with the option for re-election upon completion of the term. Additionally, Mr. Wang will serve as the Chairman of the Audit Committee, a member of the Strategic Development Committee, and a member of the Related Party Transactions Control Committee.
CHINA CINDA (01359) announced that the company recently received approval from the Financial Regulatory Authority for Mr. Wang Pengcheng (Mr. Wang) to serve as an independent non-executive director of the company (Approval No. [2026]360). Therefore, Mr. Wang will serve as an independent non-executive director of the company.
His appointment as a director will be effective from July 4, 2026, for a term of three years, and he may be re-elected upon the completion of his term. Additionally, Mr. Wang will also serve as the Chairman of the Audit Committee, a member of the Strategic Development Committee, and a member of the Related Party Transaction Control Committee.
On July 4, 2026, the company received the resignation of Mr. Lu Zhengfei, an independent non-executive director of the company. Mr. Lu submitted his resignation due to the completion of his term, resigning from his positions as independent non-executive director, Chairman of the Audit Committee, member of the Risk Management Committee, and member of the Related Party Transaction Control Committee.
Related Articles

ASTRUM FIN(08333): It is recommended to adopt the new equity purchase plan.

AIRDOC-B (02251) spent 218,000 Hong Kong dollars on repurchasing 20,400 shares on July 9th.
HYGEIA HEALTH (06078) spent approximately 1.9988 million Hong Kong dollars to repurchase 208,400 shares on July 9th.
ASTRUM FIN(08333): It is recommended to adopt the new equity purchase plan.

AIRDOC-B (02251) spent 218,000 Hong Kong dollars on repurchasing 20,400 shares on July 9th.

HYGEIA HEALTH (06078) spent approximately 1.9988 million Hong Kong dollars to repurchase 208,400 shares on July 9th.
RECOMMEND





